Reference is made to the personal placement of 48,432,000 new shares in Aqua Bio Expertise ASA (the “Firm“) positioned in March 2025 (the “Non-public Placement“) and to the next providing carried out in March and April 2025 (the “Subsequent Providing“), the place a complete of 4,111,975 new shares have been allotted (along with the brand new shares within the Non-public Placement, the “New Shares“). Reference is additional made to the decision by a rare common assembly on 25 July 2025 to extend the Firm’s share capital in reference to the Non-public Placement and the Subsequent Providing, and moreover to the decision by a rare common assembly on 7 November 2025 to scale back the Firm’s share capital by discount of the par worth of the Firm’s shares to NOK 0.10 per share (the “Share Capital Lower“).
By means of the Non-public Placement, the Firm has issued 48,432,000 New Shares at a subscription worth of NOK 0.50 per New Share, every with a par worth of NOK 0.10. Consequently, the share capital of the Firm was elevated with NOK 4,843,200 by means of the Non-public Placement.
By means of the Subsequent Providing, the Firm has issued 4,111,975 New Shares at a subscription worth of NOK 0.50 per New Shares, every with a par worth of NOK 0.10. Consequently, the share capital of the Firm was elevated with NOK 411,197.50 by means of the Subsequent Providing.
By means of the Share Capital Lower, the Firm’s share capital was decreased with NOK 261,246,580.80, by means of discount of the par worth of the Firm’s shares from NOK 2.50 to NOK 0.10 per share.
Following registration of the share capital adjustments described above, the Firm’s new share capital is NOK 16,139,671.70 divided by 161,396,717 shares, every with a par worth of NOK 0.10.
The New Shares will initially be registered with the VPS and delivered to the subscribers within the Non-public Placement and the Subsequent Providing on a separate, non-tradable ISIN, pending approval and publication of a list prospectus. Such itemizing prospectus is at the moment anticipated to be authorised and printed by finish of December 2025.
